Bausch & Lomb to Update Investors At Banc of America Securities Healthcare Conference On April 2, 2002.

Business Editors

ROCHESTER, N.Y.--(BUSINESS WIRE)--April 1, 2002

Bausch & Lomb (NYSE:BOL):

- Historical Financial Data Reclassified in Accordance with Current Emerging
Issues Task Force Guidance Available on Company Website

- Company Reaffirms 2002 Revenue and Earnings Guidance

Bausch & Lomb (NYSE:BOL) announced today that its Chief Financial Officer, Stephen C. McCluski, will be presenting an overview of the Company's operations at the Banc of America Securities Healthcare Conference in Las Vegas, Nevada on Tuesday, April 2, 2002.

Information presented by Mr. McCluski will reflect reclassified financial information which conforms with recent Emerging Issues Task Force guidance pertaining to sales incentives and consideration paid to resellers of the company's products. This guidance requires that such items be reported as offsets to revenue, with prior periods being restated for comparability purposes. Previously, such items were reported as selling, administrative and general expenses. The reclassification reduced previously reported net sales and selling, general and administrative expenses by equal amounts, resulting in no change to previously reported operating or net earnings. Reclassified income statements from 1998 through 2001, along with product category revenues for the same period, are available on the Investor Relations page of Bausch & Lomb's website at www.bausch.com.

The Company also reiterated its guidance for comparable basis full-year revenue growth and earnings per share as previously disclosed in its Form 10K for the year ended December 29, 2001.

This press release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of Bausch & Lomb. Such statements involve a number of risks and uncertainties including those concerning economic conditions, currency exchange rates, product development and introductions, the financial well-being of key customers, the successful execution of marketing strategies, the continued successful implementation of its efforts in managing and reducing costs and expenses, continued positive relations with third party financing sources, as well as the risk factors listed from time to time in the Company's SEC filings, including but not limited to the Form 10K for the year ended December 29, 2001.

Bausch & Lomb Incorporated is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology. Its core businesses include soft and rigid gas permeable contact lenses, lens care products, ophthalmic surgical and pharmaceutical products. The company is advantaged with some of the most respected brands in the world starting with its name, Bausch & Lomb, and including SofLens, PureVision, Boston, ReNu, Storz and Technolas. Founded in 1853 in Rochester, N.Y., where it continues to have its headquarters, the company had revenues of approximately $1.7 billion in 2001, and employs approximately 12,000 people in more than 50 countries. Bausch & Lomb products are available in more than 100 countries around the world. Additional information about the company can be found on Bausch & Lomb's Worldwide Web site at http://www.bausch.com. Copyright Bausch & Lomb Incorporated